uBriGene Biosciences
PrivateLast Round
VC Round
Dec 24, 2024
Total Funding Raised
$66M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
uBriGene Biosciences operates in Healthcare & Life Sciences and is based in Germantown, Maryland. Its latest recorded funding round was a VC Round in December 2024.
uBriGene Biosciences is a biotechnology company that provides contract development and manufacturing organization (CDMO) services for the cell and gene therapy industry.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
uBriGene Biosciences Comparables
Compare uBriGene Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zhejiang Innoforce Pharmaceuticals | 90% | |
| Beijing Cygenta Biotech Co., Ltd. | 88% | |
| CoJourney | 85% |
For institutional investors. Book with your work email.
uBriGene Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 24, 2024 | ||||
| Series C Extension | Apr 19, 2023 | ||||
| Series C | Sep 27, 2022 | ||||
| Series B | Sep 16, 2021 | ||||
| Series A | Dec 16, 2020 | ||||
Angel | Oct 1, 2019 |
For institutional investors. Book with your work email.
uBriGene Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BGI Co-Win | Series C |
| IDG Capital | Series C, Series B |
| 中信金石投资有限公司 | Series C |
| Innovator Capital | Series C |
| Wenzhou State-owned Financial Capital Management | Series C |
| Beijing Fangfu Venture Capital Management | Series C Extension, Series C, Series A, Series B |
| Huagai Capital | Series C, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 138% MoM, reaching 8.5K.
- Jul 20, 2026
Open roles increased to 11, representing 48% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 5, 2026
uBriGene Biosciences Inc. participates in Cell & Gene Meeting on the Mesa in Arizona from Oct 5th-7th '26, bringing its integrated cell and gene therapy technology and development capabilities to discussions with biotechnology and pharmaceutical innovators.
- attends_eventOct 2, 2026
uBriGene Biosciences Inc. exhibits at AASCP 2026 Fall Scientific Sessions in Florida from Oct 2nd-4th '26 and connects with regenerative medicine professionals at Booth #3.
- attends_eventSep 16, 2026
uBriGene Biosciences Inc. is excited to participate in the 11th CAR-TCR Summit 2026 on Sep 16–17, '26, in Massachusetts, where it will showcase its uVivo(TM) LVV Platform at Booth 20.
For institutional investors. Book with your work email.
uBriGene Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about uBriGene Biosciences's valuation, stock price, and market status.
Is uBriGene Biosciences a public or private company?
uBriGene Biosciences is a private company.
What is the current stock price of uBriGene Biosciences?
uBriGene Biosciences is a private company, so its shares have no public market price. Caplight tracks uBriGene Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is uBriGene Biosciences worth (valuation)?
Valuation information for uBriGene Biosciences is not publicly available.
Can I buy uBriGene Biosciences stock?
uBriGene Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was uBriGene Biosciences's last funding round?
uBriGene Biosciences's most recent funding round was VC Round on December 24, 2024.
Who are the main investors in uBriGene Biosciences?
Key investors in uBriGene Biosciences include IDG Capital, 中信金石投资有限公司, Huagai Capital, Qiming Venture Partners, CLSA Capital Partners.
Will uBriGene Biosciences IPO soon?
No public IPO plans have been announced for uBriGene Biosciences.
How can I track uBriGene Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in uBriGene Biosciences's shares on secondary markets.